Celltrion Introduces STEQEYMA® to Costco Members
Celltrion's STEQEYMA® (ustekinumab-stba) has been welcomed into the Costco Member Prescription Program, marking a significant milestone for patients seeking access to essential treatments. This biosimilar is a generic form of STELARA® (ustekinumab) and is designed to improve affordability and accessibility for individuals with inflammatory conditions.
Commitment to Accessibility in Healthcare
Francine Galante, Vice President of Market Access at Celltrion USA, expressed the company's dedication to enhancing patient care by reducing financial barriers associated with high-cost medications. She noted, "The addition of STEQEYMA to the Costco Member Prescription Program, alongside adalimumab-aaty, reaffirms our commitment to accessibility for critical treatments. This partnership enables us to help patients more easily afford the medications they need to manage their health effectively."
About STEQEYMA
STEQEYMA is available as both a subcutaneous injection and an intravenous infusion. It is indicated for the treatment of various conditions including plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), and ulcerative colitis (UC). This broad range of use makes STEQEYMA an essential option for many patients, particularly those affected by serious autoimmune ailments.
The Costco Member Prescription Program Explained
The Costco Member Prescription Program serves as a vital resource, offering discounted prescription prices for eligible members and their dependents. Available at Costco Specialty Pharmacies and participating locations, the program allows individuals to access STEQEYMA at a lower cost, especially beneficial for those who may be uninsured or face challenges with their insurance coverage.
Future Availability and Plans
As per the announcements, STEQEYMA will be accessible in the U.S. starting April 1 for members who wish to purchase their prescriptions with cash or are part of self-funded employer plans. This timing adds an exciting dynamic for patients eagerly awaiting affordable options for their treatments.
Safety and Important Information
While STEQEYMA is effective for many patients, it is crucial for healthcare providers and patients alike to be aware of the safety information associated with the drug. Known contraindications include significant hypersensitivity to ustekinumab products. Serious infections may occur, thus beginning treatment during an active infection is not advisable. Care should be taken with tuberculosis evaluations and patients should be monitored for potential malignancy and severe allergic reactions.
For More Information
Detailed safety information, indications, and adverse reactions associated with STEQEYMA are essential for informed treatment decisions. Healthcare practitioners should guide patients through this information to ensure a safe treatment journey. The subcutaneous injection comes in effective dosages, helping promote better treatment adherence.
About Celltrion and Its Innovations
Celltrion, a leading biopharmaceutical company, specializes in developing and manufacturing innovative therapeutics that actively improve health outcomes worldwide. With a strong focus on the biosimilar sector, Celltrion was among the first in the industry to achieve success with monoclonal antibody biosimilars. Their diverse pharmaceutical portfolio includes important therapeutic areas such as immunology and oncology.
Celltrion USA's Commitment
Established in 2018, Celltrion USA is dedicated to improving the accessibility of high-quality biologics for patients within the country. With ten biosimilars currently approved by the U.S. FDA and a commitment to ongoing innovation, the company continuously strives to meet the needs of patients through its extensive research and development efforts.
Frequently Asked Questions
What is STEQEYMA®?
STEQEYMA (ustekinumab-stba) is a biosimilar to STELARA® and is used to treat various inflammatory diseases.
How can I access STEQEYMA through Costco?
Eligible Costco members can obtain STEQEYMA at a reduced cost via the Costco Member Prescription Program at participating pharmacies.
What conditions does STEQEYMA treat?
STEQEYMA is indicated for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
When will STEQEYMA be available?
STEQEYMA will be available starting April 1 for specific plans and cash-paying patients in the U.S.
What should I know about the safety of STEQEYMA?
Patients must discuss potential contraindications and side effects with a healthcare provider before starting treatment with STEQEYMA.
